# A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

> **NCT06864026** · PHASE4 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 200 (estimated)

## Conditions studied

- Psoriatic Arthritis
- Overweight or Obesity

## Interventions

- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06864026
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06864026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06864026, "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06864026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*